Development of new medical treatment for epithelial ovarian cancer recurrence

Epithelial ovarian cancer (EOC) is the scariest gynaecological cancer. Many advances have been done with evolving knowledge, leading to the introduction of new drugs, most in maintenance setting. The antiangiogenic Bevacizumab and the three approved PARP-inhibitors—olaparib, niraparib and rucaparib—...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gland Surg
Main Authors: Mancari, Rosanna, Cutillo, Giuseppe, Bruno, Valentina, Vincenzoni, Cristina, Mancini, Emanuela, Baiocco, Ermelinda, Bruni, Simone, Vocaturo, Giuseppe, Chiofalo, Benito, Vizza, Enrico
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2020
Assuntos:
Review Article on Ovarian Cancer Recurrence
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7475356/
https://ncbi.nlm.nih.gov/pubmed/32953630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/gs-20-413
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados